{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:05:55Z","timestamp":1786982755648,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1007\/s40259-020-00430-1","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T14:04:11Z","timestamp":1592402651000},"page":"415-422","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":51,"title":["Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks"],"prefix":"10.1007","volume":"34","author":[{"given":"Salvatore","family":"Crisafulli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Isgr\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"La Corte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-7296","authenticated-orcid":false,"given":"Gianluca","family":"Trifir\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,15]]},"reference":[{"key":"430_CR1","unstructured":"European Centre for Disease Prevention and Control. Situation update worldwide, as of 24 May 2020 [Internet]. 2020. https:\/\/www.ecdc.europa.eu\/en\/covid-19-pandemic."},{"key":"430_CR2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4984","author":"DC Angus","year":"2020","unstructured":"Angus DC. Optimizing the trade-off between learning and doing in a pandemic. JAMA. 2020. https:\/\/doi.org\/10.1001\/jama.2020.4984.","journal-title":"JAMA."},{"key":"430_CR3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2009457","author":"BN Rome","year":"2020","unstructured":"Rome BN, Avorn J. Drug evaluation during the Covid-19 pandemic. N Engl J Med. 2020. https:\/\/doi.org\/10.1056\/NEJMp2009457.","journal-title":"N Engl J Med."},{"key":"430_CR4","doi-asserted-by":"crossref","first-page":"411","DOI":"10.15585\/mmwr.mm6914e1","volume":"69","author":"WE Wei","year":"2020","unstructured":"Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic transmission of SARS-CoV-2\u2014Singapore, January 23\u2013March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:411\u20135.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"issue":"10229","key":"430_CR5","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1038.","journal-title":"Lancet."},{"key":"430_CR6","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature03712","volume":"436","author":"Y Imai","year":"2005","unstructured":"Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112\u20136.","journal-title":"Nature."},{"issue":"10223","key":"430_CR7","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497\u2013506.","journal-title":"Lancet."},{"issue":"6","key":"430_CR8","doi-asserted-by":"crossref","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","volume":"19","author":"D McGonagle","year":"2020","unstructured":"McGonagle D, Sharif K, O\u2019Regan A, Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun Rev. 2020;19(6):102537.","journal-title":"Autoimmun Rev"},{"key":"430_CR9","doi-asserted-by":"crossref","first-page":"3594","DOI":"10.1038\/ncomms4594","volume":"5","author":"Z Zou","year":"2014","unstructured":"Zou Z, Yan Y, Shu Y, Gao R, Sun Y, Li X, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594.","journal-title":"Nat Commun."},{"key":"430_CR10","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.18.20024364","author":"B Diao","year":"2020","unstructured":"Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, et al. Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.02.18.20024364.","journal-title":"medRxiv"},{"issue":"1","key":"430_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40249-020-00646-x","volume":"9","author":"SP Adhikari","year":"2020","unstructured":"Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29.","journal-title":"Infect Dis Poverty."},{"key":"430_CR12","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3527420","author":"M Yang","year":"2020","unstructured":"Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. SSRN Electron J. 2020. https:\/\/doi.org\/10.2139\/ssrn.3527420.","journal-title":"SSRN Electron J."},{"issue":"7798","key":"430_CR13","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature."},{"issue":"9371","key":"430_CR14","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1016\/S0140-6736(03)13412-5","volume":"361","author":"JSM Peiris","year":"2003","unstructured":"Peiris JSM, Chu CM, Cheng VCC, Chan KS, Hung IFN, Poon LLM, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003;361(9371):1767\u201372.","journal-title":"Lancet."},{"key":"430_CR15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.0105-2896.2006.00382.x","volume":"211","author":"MF Mescher","year":"2006","unstructured":"Mescher MF, Curtsinger JM, Agarwal P, Casey KA, Gerner M, Hammerbeck CD, et al. Signals required for programming effector and memory development by CD8+ T cells. Immunol Rev. 2006;211:81\u201392.","journal-title":"Immunol Rev."},{"key":"430_CR16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev-immunol-030409-101212","volume":"28","author":"J Zhu","year":"2010","unstructured":"Zhu J, Yamane H, Paul WE. Differentiation of effector CD4 T cell populations. Annu Rev Immunol. 2010;28:445\u201389.","journal-title":"Annu Rev Immunol."},{"issue":"3","key":"430_CR17","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.2067","volume":"210","author":"L He","year":"2006","unstructured":"He L, Ding Y, Zhang Q, Che X, He Y, Shen H, et al. Expression of elevated levels of pro-inflammatory cytokines in SARS-CoV-infected ACE2+ cells in SARS patients: Relation to the acute lung injury and pathogenesis of SARS. J Pathol. 2006;210(3):288\u201397.","journal-title":"J Pathol."},{"issue":"11","key":"430_CR18","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/nm1492","volume":"12","author":"DG Brooks","year":"2006","unstructured":"Brooks DG, Trifilo MJ, Edelmann KH, Teyton L, McGavern DB, Oldstone MBA. Interleukin-10 determines viral clearance or persistence in vivo. Nat Med. 2006;12(11):1301\u20139.","journal-title":"Nat Med."},{"issue":"18","key":"430_CR19","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1056\/NEJMoa2002032","volume":"382","author":"WJ Guan","year":"2020","unstructured":"Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708\u201320.","journal-title":"N Engl J Med."},{"issue":"2","key":"430_CR20","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.virol.2011.09.003","volume":"420","author":"Y Liao","year":"2011","unstructured":"Liao Y, Wang X, Huang M, Tam JP, Liu DX. Regulation of the p38 mitogen-activated protein kinase and dual-specificity phosphatase 1 feedback loop modulates the induction of interleukin 6 and 8 in cells infected with coronavirus infectious bronchitis virus. Virology. 2011;420(2):106\u201316.","journal-title":"Virology."},{"key":"430_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2020.02.12.945576","author":"Y Zhou","year":"2020","unstructured":"Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.02.12.945576.","journal-title":"bioRxiv."},{"issue":"4","key":"430_CR22","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","volume":"122","author":"M Mihara","year":"2012","unstructured":"Mihara M, Hashizume M, Yoshida H, Suzuki M, Shiina M. IL-6\/IL-6 receptor system and its role in physiological and pathological conditions. Clin Sci. 2012;122(4):143\u201359.","journal-title":"Clin Sci."},{"issue":"5","key":"430_CR23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1089\/jir.2005.25.241","volume":"25","author":"SA Jones","year":"2005","unstructured":"Jones SA, Richards PJ, Scheller J, Rose-John S. IL-6 transsignaling: the in vivo consequences. J Interf Cytokine Res. 2005;25(5):241\u201353.","journal-title":"J Interf Cytokine Res."},{"issue":"2","key":"430_CR24","first-page":"10.23812","volume":"34","author":"P Conti","year":"2020","unstructured":"Conti P, Gallenga CE, Tet\u00e8 G, Caraffa A, Ronconi G, Younes A, et al. How to reduce the likelihood of coronavirus-19 (CoV-19 or SARS-CoV-2) infection and lung inflammation mediated by IL-1. J Biol Regul Homeost Agents. 2020;34(2):10.23812.","journal-title":"J Biol Regul Homeost Agents."},{"key":"430_CR25","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3389\/fmicb.2019.00050","volume":"10","author":"IY Chen","year":"2019","unstructured":"Chen IY, Moriyama M, Chang MF, Ichinohe T. Severe acute respiratory syndrome coronavirus viroporin 3a activates the NLRP3 inflammasome. Front Microbiol. 2019;10:50.","journal-title":"Front Microbiol."},{"key":"430_CR26","doi-asserted-by":"crossref","first-page":"105738","DOI":"10.1016\/j.biocel.2020.105738","volume":"122","author":"NS Farag","year":"2020","unstructured":"Farag NS, Breitinger U, Breitinger HG, El Azizi MA. Viroporins and inflammasomes: a key to understand virus-induced inflammation. Int J Biochem Cell Biol. 2020;122:105738.","journal-title":"Int J Biochem Cell Biol."},{"issue":"5","key":"430_CR27","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/ni.1861","volume":"11","author":"T Ichinohe","year":"2010","unstructured":"Ichinohe T, Pang IK, Iwasaki A. Influenza virus activates inflammasomes via its intracellular M2 ion channel. Nat Immunol. 2010;11(5):404\u201310.","journal-title":"Nat Immunol."},{"issue":"2","key":"430_CR28","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2004.10.001","volume":"65","author":"YJ Tan","year":"2005","unstructured":"Tan YJ, Lim SG, Hong W. Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res. 2005;65(2):69\u201378.","journal-title":"Antiviral Res."},{"issue":"2","key":"430_CR29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","volume":"29","author":"A Ogata","year":"2019","unstructured":"Ogata A, Kato Y, Higa S, Yoshizaki K. IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review. Mod Rheumatol. 2019;29(2):258\u201367.","journal-title":"Mod Rheumatol."},{"issue":"1","key":"430_CR30","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/cei.12966","volume":"189","author":"K Schinnerling","year":"2017","unstructured":"Schinnerling K, Aguill\u00f3n JC, Catal\u00e1n D, Soto L. The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis. Clin Exp Immunol. 2017;189(1):12\u201320.","journal-title":"Clin Exp Immunol."},{"issue":"10229","key":"430_CR31","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","volume":"395","author":"P Mehta","year":"2020","unstructured":"Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033\u20134.","journal-title":"Lancet."},{"issue":"4","key":"430_CR32","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/annrheumdis-2012-202470","volume":"72","author":"MM Schoels","year":"2013","unstructured":"Schoels MM, Van Der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72(4):583\u20139.","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"430_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s10067-016-3435-2","volume":"36","author":"R Alfonso-Cristancho","year":"2017","unstructured":"Alfonso-Cristancho R, Armstrong N, Arjunji R, Riemsma R, Worthy G, Ganguly R, et al. Comparative effectiveness of biologics for the management of rheumatoid arthritis: systematic review and network meta-analysis. Clin Rheumatol. 2017;36(1):25\u201334.","journal-title":"Clin Rheumatol."},{"issue":"6","key":"430_CR34","first-page":"899","volume":"35","author":"B Haraoui","year":"2017","unstructured":"Haraoui B, Casado G, Czirj\u00e1k L, Taylor A, Bernasconi C, Reiss W, et al. Patterns of tocilizumab use, effectiveness and safety in patients with rheumatoid arthritis: core data results from a set of multinational observational studies. Clin Exp Rheumatol. 2017;35(6):899\u2013906.","journal-title":"Clin Exp Rheumatol."},{"issue":"224","key":"430_CR35","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6(224):224ra25.","journal-title":"Sci Transl Med."},{"issue":"2","key":"430_CR36","first-page":"119","volume":"20","author":"SL Maude","year":"2014","unstructured":"Maude SL, Barrett D, Teachey DT, Grupp SA. Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (United States). 2014;20(2):119\u201322.","journal-title":"Cancer J (United States)"},{"issue":"2","key":"430_CR37","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","volume":"45","author":"JC Fitzgerald","year":"2017","unstructured":"Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124\u201331.","journal-title":"Crit Care Med."},{"issue":"26","key":"430_CR38","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","volume":"127","author":"JN Brudno","year":"2016","unstructured":"Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321\u201330.","journal-title":"Blood."},{"issue":"16","key":"430_CR39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507\u201317.","journal-title":"N Engl J Med."},{"issue":"25","key":"430_CR40","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","volume":"74","author":"RM Alvi","year":"2019","unstructured":"Alvi RM, Frigault MJ, Fradley MG, Jain MD, Mahmood SS, Awadalla M, et al. Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T). J Am Coll Cardiol. 2019;74(25):3099\u2013108.","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"430_CR41","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1200\/JCO.2014.56.2025","volume":"33","author":"JN Kochenderfer","year":"2015","unstructured":"Kochenderfer JN, Dudley ME, Kassim SH, Somerville RPT, Carpenter RO, Maryalice SS, et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015;33(6):540\u20139.","journal-title":"J Clin Oncol."},{"issue":"2","key":"430_CR42","first-page":"e124","volume":"45","author":"NV Frey","year":"2014","unstructured":"Frey NV, Levine LB, Lacey SF, Grupp SA, Maude SL, Schuster SJ, Shaw P, Hwang W-T, Wasik MA, Obstfeld A, Leung M, Shen A, Ericson SG, Melenhorst JJ, June CH, Porter D. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood. 2014;45(2):e124\u201331.","journal-title":"Blood."},{"issue":"16","key":"430_CR43","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","volume":"368","author":"SA Grupp","year":"2013","unstructured":"Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509\u201318.","journal-title":"N Engl J Med."},{"issue":"9","key":"430_CR44","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S1470-2045(14)70319-5","volume":"15","author":"F Van Rhee","year":"2014","unstructured":"Van Rhee F, Wong RS, Munshi N, Rossi JF, Ke XY, Foss\u00e5 A, et al. Siltuximab for multicentric Castleman\u2019s disease: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2014;15(9):966\u201374.","journal-title":"Lancet Oncol."},{"issue":"10","key":"430_CR45","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1080\/14712598.2016.1217988","volume":"16","author":"RR June","year":"2016","unstructured":"June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303\u20139.","journal-title":"Expert Opin Biol Ther."},{"key":"430_CR46","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.2147\/DDDT.S100302","volume":"11","author":"MG Raimondo","year":"2017","unstructured":"Raimondo MG, Biggioggero M, Crotti C, Becciolini A, Favalli EG. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Dev Ther. 2017;11:1593\u2013603.","journal-title":"Drug Des Dev Ther."},{"issue":"26","key":"430_CR47","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1200\/JCO.2017.72.8519","volume":"35","author":"CJ Turtle","year":"2017","unstructured":"Turtle CJ, Hay KA, Hanafi LA, Li D, Cherian S, Chen X, et al. Durable molecular remissions in chronic lymphocytic leukemia treated with CD19-Specific chimeric antigen Receptor-modified T cells after failure of ibrutinib. J Clin Oncol. 2017;35(26):3010\u201320.","journal-title":"J Clin Oncol."},{"issue":"1","key":"430_CR48","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s40259-018-0324-z","volume":"33","author":"BR Dholaria","year":"2019","unstructured":"Dholaria BR, Bachmeier CA, Locke F. Mechanisms and management of chimeric antigen receptor T-cell therapy-related toxicities. BioDrugs. 2019;33(1):45\u201360.","journal-title":"BioDrugs."},{"issue":"20","key":"430_CR49","doi-asserted-by":"crossref","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci USA. 2020;117(20):10970\u20135.","journal-title":"Proc Natl Acad Sci USA."},{"key":"430_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25801","author":"P Luo","year":"2020","unstructured":"Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: a single center experience. J Med Virol. 2020. https:\/\/doi.org\/10.1002\/jmv.25801.","journal-title":"J Med Virol."},{"key":"430_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.300","author":"J-M Michot","year":"2020","unstructured":"Michot J-M, Albiges L, Chaput N, Saada V, Pommeret F, Griscelli F, et al. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report. Ann Oncol. 2020. https:\/\/doi.org\/10.1016\/j.annonc.2020.03.300.","journal-title":"Ann Oncol."},{"issue":"7","key":"430_CR52","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.autrev.2020.102568","volume":"19","author":"P Toniati","year":"2020","unstructured":"Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: a single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. https:\/\/doi.org\/10.1016\/j.autrev.2020.102568.","journal-title":"Autoimmun Rev."},{"key":"430_CR53","unstructured":"Office of the Chinese Medicine Bureau. State Health Office Medical Letter [2020] No. 184: Notice regarding the issuance of a new coronavirus pneumonia diagnosis and treatment plan (for trial implementation of the seventh edition) [Internet]. http:\/\/www.gov.cn\/zhengce\/zhengceku\/2020-03\/04\/content_5486705.htm. Accessed 26 May 2020."},{"issue":"1","key":"430_CR54","doi-asserted-by":"crossref","first-page":"e000878","DOI":"10.1136\/jitc-2020-000878","volume":"8","author":"PA Ascierto","year":"2020","unstructured":"Ascierto PA, Fox B, Urba W, Carrizosa Anderson A, Atkins MB, Borden EC, Brahmer J, Butterfield LH, Cesano A, Chen D, de Gruijl T, Dillman RO, Drake CG, Emens LA, Gajewski TF, Gulley JL, Hodi FS, Hwu P, Kaufman D, Kaufman H, Lotze MM. Insights from immuno-oncology: the society for immunotherapy of cancer statement on access to IL-6-targeting therapies for COVID-19. J Immunother Cancer. 2020;8(1):e000878.","journal-title":"J Immunother Cancer."},{"issue":"12","key":"430_CR55","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1093\/cid\/ciu185","volume":"58","author":"IS Kourbeti","year":"2014","unstructured":"Kourbeti IS, Ziakas PD, Mylonakis E. Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis. Clin Infect Dis. 2014;58(12):1649\u201357.","journal-title":"Clin Infect Dis."},{"key":"430_CR56","unstructured":"European Medicines Agency. Tocilizumab: summary of product characteristics [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/roactemra-epar-product-information_en.pdf. Accessed 26 May 2020."},{"key":"430_CR57","unstructured":"European Medicines Agency. Sarilumab: summary of product characteristics [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kevzara-epar-product-information_en.pdf. Accessed 26 May 2020."},{"key":"430_CR58","unstructured":"European Medicines Agency. Siltuximab: summary of product characteristics [Internet]. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sylvant-epar-product-information_en.pdf. Accessed 26 May 2020."},{"issue":"11","key":"430_CR59","doi-asserted-by":"crossref","first-page":"648","DOI":"10.5414\/CP201549","volume":"49","author":"S Grange","year":"2011","unstructured":"Grange S, Schmitt C, Banken L, Kuhn B, Zhang X. Thorough QT\/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. Int J Clin Pharmacol Ther. 2011;49(11):648\u201355.","journal-title":"Int J Clin Pharmacol Ther."},{"issue":"1\u20132","key":"430_CR60","first-page":"164","volume":"61","author":"O Shovman","year":"2014","unstructured":"Shovman O, Shoenfeld Y, Langevitz P. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature. Immunol Res. 2014;61(1\u20132):164\u20138.","journal-title":"Immunol Res."},{"issue":"8","key":"430_CR61","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist."},{"issue":"10","key":"430_CR62","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/1947601910397187","volume":"1","author":"SS Jatiani","year":"2010","unstructured":"Jatiani SS, Baker SJ, Silverman LR, Premkumar Reddy E. JAK\/STAT pathways in cytokine signaling and myeloproliferative disorders: approaches for targeted therapies. Genes Cancer. 2010;1(10):979\u201393.","journal-title":"Genes Cancer."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00430-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-020-00430-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-020-00430-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T19:15:55Z","timestamp":1623698155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-020-00430-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,15]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["430"],"URL":"https:\/\/doi.org\/10.1007\/s40259-020-00430-1","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,15]]},"assertion":[{"value":"15 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to prepare this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"G Trifir\u00f2 has served on advisory boards for Sandoz, Hospira, Sanofi, Biogen, Ipsen, and Shire; is a consultant for Otsuka; is the principal investigator of observational studies funded by several pharmaceutical companies (e.g., Amgen, AstraZeneca, Daiichi Sankyo, and IBSA) to University of Messina; and is scientific coordinator of the Master\u2019s program \u2018Pharmacovigilance, pharmacoepidemiology and pharmacoeconomics: real-world data evaluations\u2019 at University of Messina, which is partly funded by several pharmaceutical companies. Salvatore Crisafulli, Valentina Isgr\u00f2, Laura La Corte, and Fabiola Atzeni have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}